Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT00720668 Recruiting - Clinical trials for Hepatocellular Carcinoma

The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma

HBV-HCC
Start date: June 2006
Phase: N/A
Study type: Observational

This study aim to find out the risk of exacerbation of chronic hepatitis B after percutaneous radiofrequency ablation (RFA) or hepatectomy for HCC, and it's effect to treatment outcome.

NCT ID: NCT00707681 Recruiting - Clinical trials for Hepatocellular Carcinoma

Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)

Start date: March 2008
Phase: Phase 2
Study type: Interventional

To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients using European Organization for Research and Treatment of Cancer (EORTC) QLQ C-30 questionnaire.

NCT ID: NCT00644020 Recruiting - Clinical trials for Hepatocellular Carcinoma

Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients

Start date: December 2007
Phase: N/A
Study type: Observational

The investigation is a randomized, double-blind, placebo involved and multi-center clinical trial. All subjects are assigned to 4 groups, including 3mg, 6mg, 12mg per day and placebo group. Each group includes 25 subjects, who have hepatic-cellular carcinoma accompanied with branch vein thrombosis. They receive investigational drug 40 days after resection surgery. Each cycle lasts 4 to 6 days with an interval of 29 days in all 6 cycles.

NCT ID: NCT00629668 Recruiting - Clinical trials for Hepatocellular Carcinoma

Genetic Polymorphisms of TNF-α Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease

Start date: January 2007
Phase: N/A
Study type: Interventional

The prognosis of Hepatitis B virus (HBV)infection varies from minimal progressive liver disease to cirrhosis or hepatocellular carcinoma (HCC).Both viral and host genetic factors contribute to disease severity. Cytokine gene polymorphism has been regarded affecting prognosis of disease. By detecting HBV genotyping and tumor necrosis factor-alpha polymorphism, this study aime to assess their effects and interaction on disease severity of HBV-related chronic liver disease and HCC.

NCT ID: NCT00557024 Recruiting - Clinical trials for Hepatocellular Carcinoma

Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

RT-RFA
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of the investigators study is to prospectively evaluate whether radiotherapy as an adjuvant therapy after RFA will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC) or not.

NCT ID: NCT00556803 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma

TACE-RFA
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to prospectively evaluate whether transcatheter arterial chemoembolization (TACE) will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC) or not.

NCT ID: NCT00555334 Recruiting - Clinical trials for Hepatocellular Carcinoma

Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

LAM-RFA
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of the investigators' study is to prospectively evaluate whether nucleoid antiviral therapy will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC).

NCT ID: NCT00554905 Recruiting - Clinical trials for Hepatocellular Carcinoma

Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma

RFA and TACE
Start date: October 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to prospectively evaluate whether combined RFA and TACE (RFA-TACE) result in better survival outcomes than RFA alone in patients with HCC.

NCT ID: NCT00554125 Recruiting - Clinical trials for Hepatocellular Carcinoma

Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria

Start date: August 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the influence of sirolimus on outcome after OLT for HCC exceeding Milan criteria.

NCT ID: NCT00522405 Recruiting - Clinical trials for Hepatocellular Carcinoma

Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma

Start date: October 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Background Hepatocellular carcinoma, a malignant tumor of liver is one of the most common cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care hospital receives about two to three cases of Hepatocellular carcinoma (HCC) each day in our Gastroenterology out patient department. Most of these patients present late when the disease is already advanced and no curative therapies can be offered. At this stage, palliative therapy forms the mainstay of treatment. This includes TACE or Oral chemotherapy. Whether oral chemotherapy administered along with TACE potentiates the effect and further prolongs survival, needs to be ascertained. No studies of this kind are available. This prospective study is therefore designed to address this issue.